Lymphatic manifestations of lymphangioleiomyomatosis.
Identifieur interne : 001449 ( PubMed/Checkpoint ); précédent : 001448; suivant : 001450Lymphatic manifestations of lymphangioleiomyomatosis.
Auteurs : R. Gupta ; M. Kitaichi ; Y. Inoue ; R. Kotloff ; F X MccormackSource :
- Lymphology [ 0024-7766 ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Antinéoplasiques (usage thérapeutique), Facteurs de risque, Femelle, Humains, Lymphangiogenèse (), Lymphangiogenèse (génétique), Lymphangioléiomyomatose (anatomopathologie), Lymphangioléiomyomatose (génétique), Lymphangioléiomyomatose (métabolisme), Lymphangioléiomyomatose (traitement médicamenteux), Lymphangioléiomyomatose (épidémiologie), Marqueurs biologiques (métabolisme), Phénotype, Pronostic, Protéines et peptides de signalisation intercellulaire (métabolisme), Prédisposition génétique à une maladie, Thérapie moléculaire ciblée, Transduction du signal, Vaisseaux lymphatiques (), Vaisseaux lymphatiques (anatomopathologie), Vaisseaux lymphatiques (métabolisme).
- MESH :
- anatomopathologie : Lymphangioléiomyomatose, Vaisseaux lymphatiques.
- génétique : Lymphangiogenèse, Lymphangioléiomyomatose.
- métabolisme : Lymphangioléiomyomatose, Marqueurs biologiques, Protéines et peptides de signalisation intercellulaire, Vaisseaux lymphatiques.
- traitement médicamenteux : Lymphangioléiomyomatose.
- usage thérapeutique : Antinéoplasiques.
- épidémiologie : Lymphangioléiomyomatose.
- Animaux, Facteurs de risque, Femelle, Humains, Lymphangiogenèse, Phénotype, Pronostic, Prédisposition génétique à une maladie, Thérapie moléculaire ciblée, Transduction du signal, Vaisseaux lymphatiques.
English descriptors
- KwdEn :
- Animals, Antineoplastic Agents (therapeutic use), Biomarkers (metabolism), Female, Genetic Predisposition to Disease, Humans, Intercellular Signaling Peptides and Proteins (metabolism), Lymphangiogenesis (drug effects), Lymphangiogenesis (genetics), Lymphangioleiomyomatosis (drug therapy), Lymphangioleiomyomatosis (epidemiology), Lymphangioleiomyomatosis (genetics), Lymphangioleiomyomatosis (metabolism), Lymphangioleiomyomatosis (pathology), Lymphatic Vessels (drug effects), Lymphatic Vessels (metabolism), Lymphatic Vessels (pathology), Molecular Targeted Therapy, Phenotype, Prognosis, Risk Factors, Signal Transduction.
- MESH :
- chemical , metabolism : Biomarkers, Intercellular Signaling Peptides and Proteins.
- chemical , therapeutic use : Antineoplastic Agents.
- drug effects : Lymphangiogenesis, Lymphatic Vessels.
- drug therapy : Lymphangioleiomyomatosis.
- epidemiology : Lymphangioleiomyomatosis.
- genetics : Lymphangiogenesis, Lymphangioleiomyomatosis.
- metabolism : Lymphangioleiomyomatosis, Lymphatic Vessels.
- pathology : Lymphangioleiomyomatosis, Lymphatic Vessels.
- Animals, Female, Genetic Predisposition to Disease, Humans, Molecular Targeted Therapy, Phenotype, Prognosis, Risk Factors, Signal Transduction.
Abstract
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low grade, metastasizing neoplasm, associated with cellular invasion and cystic destruction of the pulmonary parenchyma. Although the source of LAM cells that infiltrate the lung is unknown, available evidence indicates that the disease spreads primarily through lymphatic channels, often involving abdominal, axial, and retroperitoneal nodes, suggestive of an origin in the pelvis. LAM cells harbor mutations in tuberous sclerosis genes and produce lymphangiogenic growth factors, which facilitate access to and movement through the lymphatic system and likely play an important role in destructive tissue remodeling in the lung. Lymphatic manifestations of LAM include thoracic duct wall invasion, lymphangioleiomyoma formation, chylous fluid collections in the peritoneal, pleural, and pericardial spaces, chyloptysis, chylocolporrheal chylometrorrhea, chyle leak from the umbilicus, chylous pulmonary congestion, and lower extremity lymphedema. LAM lesions express lymphangiogenic growth factors VEGF-C and VEGF-D; growth factor receptors, VEGFR-2 and VEGFR-3; and markers LYVE-1 and podoplanin, and are laced with chaotic lymphatic channels. Serum VEGF-D is elevated in 70% of patients with LAM and is a clinically useful diagnostic and prognostic biomarker. Molecular targeted therapy with sirolimus stabilizes lung function, is anti-lymphangiogenic, and is highly effective for the lymphatic and chylous complications of LAM. Future trials in patients with LAM who have lymphatic manifestations or elevated serum VEGF-D will likely focus on the VEGF-C/VEGF-D/VEGFR-3 axis.
PubMed: 25420303
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25420303Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lymphatic manifestations of lymphangioleiomyomatosis.</title><author><name sortKey="Gupta, R" sort="Gupta, R" uniqKey="Gupta R" first="R" last="Gupta">R. Gupta</name></author><author><name sortKey="Kitaichi, M" sort="Kitaichi, M" uniqKey="Kitaichi M" first="M" last="Kitaichi">M. Kitaichi</name></author><author><name sortKey="Inoue, Y" sort="Inoue, Y" uniqKey="Inoue Y" first="Y" last="Inoue">Y. Inoue</name></author><author><name sortKey="Kotloff, R" sort="Kotloff, R" uniqKey="Kotloff R" first="R" last="Kotloff">R. Kotloff</name></author><author><name sortKey="Mccormack, F X" sort="Mccormack, F X" uniqKey="Mccormack F" first="F X" last="Mccormack">F X Mccormack</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25420303</idno><idno type="pmid">25420303</idno><idno type="wicri:Area/PubMed/Corpus">001193</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001193</idno><idno type="wicri:Area/PubMed/Curation">001193</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001193</idno><idno type="wicri:Area/PubMed/Checkpoint">001193</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001193</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lymphatic manifestations of lymphangioleiomyomatosis.</title><author><name sortKey="Gupta, R" sort="Gupta, R" uniqKey="Gupta R" first="R" last="Gupta">R. Gupta</name></author><author><name sortKey="Kitaichi, M" sort="Kitaichi, M" uniqKey="Kitaichi M" first="M" last="Kitaichi">M. Kitaichi</name></author><author><name sortKey="Inoue, Y" sort="Inoue, Y" uniqKey="Inoue Y" first="Y" last="Inoue">Y. Inoue</name></author><author><name sortKey="Kotloff, R" sort="Kotloff, R" uniqKey="Kotloff R" first="R" last="Kotloff">R. Kotloff</name></author><author><name sortKey="Mccormack, F X" sort="Mccormack, F X" uniqKey="Mccormack F" first="F X" last="Mccormack">F X Mccormack</name></author></analytic><series><title level="j">Lymphology</title><idno type="ISSN">0024-7766</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antineoplastic Agents (therapeutic use)</term><term>Biomarkers (metabolism)</term><term>Female</term><term>Genetic Predisposition to Disease</term><term>Humans</term><term>Intercellular Signaling Peptides and Proteins (metabolism)</term><term>Lymphangiogenesis (drug effects)</term><term>Lymphangiogenesis (genetics)</term><term>Lymphangioleiomyomatosis (drug therapy)</term><term>Lymphangioleiomyomatosis (epidemiology)</term><term>Lymphangioleiomyomatosis (genetics)</term><term>Lymphangioleiomyomatosis (metabolism)</term><term>Lymphangioleiomyomatosis (pathology)</term><term>Lymphatic Vessels (drug effects)</term><term>Lymphatic Vessels (metabolism)</term><term>Lymphatic Vessels (pathology)</term><term>Molecular Targeted Therapy</term><term>Phenotype</term><term>Prognosis</term><term>Risk Factors</term><term>Signal Transduction</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lymphangiogenèse ()</term><term>Lymphangiogenèse (génétique)</term><term>Lymphangioléiomyomatose (anatomopathologie)</term><term>Lymphangioléiomyomatose (génétique)</term><term>Lymphangioléiomyomatose (métabolisme)</term><term>Lymphangioléiomyomatose (traitement médicamenteux)</term><term>Lymphangioléiomyomatose (épidémiologie)</term><term>Marqueurs biologiques (métabolisme)</term><term>Phénotype</term><term>Pronostic</term><term>Protéines et peptides de signalisation intercellulaire (métabolisme)</term><term>Prédisposition génétique à une maladie</term><term>Thérapie moléculaire ciblée</term><term>Transduction du signal</term><term>Vaisseaux lymphatiques ()</term><term>Vaisseaux lymphatiques (anatomopathologie)</term><term>Vaisseaux lymphatiques (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers</term><term>Intercellular Signaling Peptides and Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphangioléiomyomatose</term><term>Vaisseaux lymphatiques</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphangiogenesis</term><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangioleiomyomatosis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Lymphangioleiomyomatosis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lymphangiogenesis</term><term>Lymphangioleiomyomatosis</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Lymphangiogenèse</term><term>Lymphangioléiomyomatose</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphangioleiomyomatosis</term><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Lymphangioléiomyomatose</term><term>Marqueurs biologiques</term><term>Protéines et peptides de signalisation intercellulaire</term><term>Vaisseaux lymphatiques</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphangioleiomyomatosis</term><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangioléiomyomatose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Lymphangioléiomyomatose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Genetic Predisposition to Disease</term><term>Humans</term><term>Molecular Targeted Therapy</term><term>Phenotype</term><term>Prognosis</term><term>Risk Factors</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Lymphangiogenèse</term><term>Phénotype</term><term>Pronostic</term><term>Prédisposition génétique à une maladie</term><term>Thérapie moléculaire ciblée</term><term>Transduction du signal</term><term>Vaisseaux lymphatiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphangioleiomyomatosis (LAM) is a slowly progressive, low grade, metastasizing neoplasm, associated with cellular invasion and cystic destruction of the pulmonary parenchyma. Although the source of LAM cells that infiltrate the lung is unknown, available evidence indicates that the disease spreads primarily through lymphatic channels, often involving abdominal, axial, and retroperitoneal nodes, suggestive of an origin in the pelvis. LAM cells harbor mutations in tuberous sclerosis genes and produce lymphangiogenic growth factors, which facilitate access to and movement through the lymphatic system and likely play an important role in destructive tissue remodeling in the lung. Lymphatic manifestations of LAM include thoracic duct wall invasion, lymphangioleiomyoma formation, chylous fluid collections in the peritoneal, pleural, and pericardial spaces, chyloptysis, chylocolporrheal chylometrorrhea, chyle leak from the umbilicus, chylous pulmonary congestion, and lower extremity lymphedema. LAM lesions express lymphangiogenic growth factors VEGF-C and VEGF-D; growth factor receptors, VEGFR-2 and VEGFR-3; and markers LYVE-1 and podoplanin, and are laced with chaotic lymphatic channels. Serum VEGF-D is elevated in 70% of patients with LAM and is a clinically useful diagnostic and prognostic biomarker. Molecular targeted therapy with sirolimus stabilizes lung function, is anti-lymphangiogenic, and is highly effective for the lymphatic and chylous complications of LAM. Future trials in patients with LAM who have lymphatic manifestations or elevated serum VEGF-D will likely focus on the VEGF-C/VEGF-D/VEGFR-3 axis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25420303</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>25</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-7766</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lymphology</Title><ISOAbbreviation>Lymphology</ISOAbbreviation></Journal><ArticleTitle>Lymphatic manifestations of lymphangioleiomyomatosis.</ArticleTitle><Pagination><MedlinePgn>106-17</MedlinePgn></Pagination><Abstract><AbstractText>Lymphangioleiomyomatosis (LAM) is a slowly progressive, low grade, metastasizing neoplasm, associated with cellular invasion and cystic destruction of the pulmonary parenchyma. Although the source of LAM cells that infiltrate the lung is unknown, available evidence indicates that the disease spreads primarily through lymphatic channels, often involving abdominal, axial, and retroperitoneal nodes, suggestive of an origin in the pelvis. LAM cells harbor mutations in tuberous sclerosis genes and produce lymphangiogenic growth factors, which facilitate access to and movement through the lymphatic system and likely play an important role in destructive tissue remodeling in the lung. Lymphatic manifestations of LAM include thoracic duct wall invasion, lymphangioleiomyoma formation, chylous fluid collections in the peritoneal, pleural, and pericardial spaces, chyloptysis, chylocolporrheal chylometrorrhea, chyle leak from the umbilicus, chylous pulmonary congestion, and lower extremity lymphedema. LAM lesions express lymphangiogenic growth factors VEGF-C and VEGF-D; growth factor receptors, VEGFR-2 and VEGFR-3; and markers LYVE-1 and podoplanin, and are laced with chaotic lymphatic channels. Serum VEGF-D is elevated in 70% of patients with LAM and is a clinically useful diagnostic and prognostic biomarker. Molecular targeted therapy with sirolimus stabilizes lung function, is anti-lymphangiogenic, and is highly effective for the lymphatic and chylous complications of LAM. Future trials in patients with LAM who have lymphatic manifestations or elevated serum VEGF-D will likely focus on the VEGF-C/VEGF-D/VEGFR-3 axis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kitaichi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kotloff</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McCormack</LastName><ForeName>F X</ForeName><Initials>FX</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lymphology</MedlineTA><NlmUniqueID>0155112</NlmUniqueID><ISSNLinking>0024-7766</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lymphology. 2015 Mar;48(1):51-2</RefSource><PMID Version="1">26333214</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lymphology. 2015 Mar;48(1):52</RefSource><PMID Version="1">26333215</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042583" MajorTopicYN="Y">Lymphangiogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018192" MajorTopicYN="Y">Lymphangioleiomyomatosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25420303</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Gupta, R" sort="Gupta, R" uniqKey="Gupta R" first="R" last="Gupta">R. Gupta</name><name sortKey="Inoue, Y" sort="Inoue, Y" uniqKey="Inoue Y" first="Y" last="Inoue">Y. Inoue</name><name sortKey="Kitaichi, M" sort="Kitaichi, M" uniqKey="Kitaichi M" first="M" last="Kitaichi">M. Kitaichi</name><name sortKey="Kotloff, R" sort="Kotloff, R" uniqKey="Kotloff R" first="R" last="Kotloff">R. Kotloff</name><name sortKey="Mccormack, F X" sort="Mccormack, F X" uniqKey="Mccormack F" first="F X" last="Mccormack">F X Mccormack</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25420303
|texte= Lymphatic manifestations of lymphangioleiomyomatosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25420303" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |